(2S)-2,5-dimethylhexan-1-ol | 103184-98-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2S)-2,5-dimethylhexan-1-ol
• CAS: 103184-98-1
• 化学式: C₈H₁₈O
• 分子量: 130.23
• InChiKey: OBOHUKJIPIBYTA-QMMMGPOBSA-N

物化性质

• 沸点：
  179.5±0.0 °C(Predicted)
• 密度：
  0.819±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-methyl-4-hexyn-3-one 在 palladium on activated charcoal lithium aluminium tetrahydride 、 正丁基锂 、 (R)-alpine borane 、 氢气 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 21.0h， 生成 (2S)-2,5-dimethylhexan-1-ol
  参考文献：
  名称：

  在三烷基锡烷基甲基烯丙基醚的阴离子的[2,3]σ重排中的手性转移研究。（2R）-3-苄氧基-2-甲基丙醇的立体定向合成。

  摘要：

  在衍生自三烷基锡烷基甲基（）-或（）-烯丙基醚的阴离子的[2,3]σ重排中观察到几乎完全的手性转移。

  DOI：

  10.1016/s0040-4039(01)80840-6

文献信息

• NOVEL SELECTIVE ANDROGEN RECEPTOR MODULATORS
  申请人：Pfizer Inc.

  公开号：US20140155390A1

  公开（公告）日：2014-06-05

  The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or —CR 0 —, where R 0 is hydrogen, C 1 -C 6 linear or branched chain alkyl, etc., Z is —CR e —, or, —N—, where R e is hydrogen, C 1 -C 6 linear or branched chain alkyl,etc.; R 1 is hydrogen, C 1 -C 6 linear or branched chain alkyl, etc.; R 2 are independently hydrogen or C 1 -C 6 linear or branched chain alkyl; R 3 and R 4 are independently hydrogen, C 1 -C 6 linear or branched chain alkyl, etc.;. R 5 and R 6 are independently hydrogen or C 1 -C 6 linear or branched chain alkyl, etc.; R 8 is hydrogen, C 1 -C 6 linear or branched chain alkyl, etc.; R 9 and R 10 are independently hydrogen or C 1 -C 6 linear or branched chain alkyl, etc.; Q is —CO—, —(CH 2 ) q —, —(CHR s ) q —, or (CR s R t ) q —, where R s and R t are independently C 1 -C 6 linear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl; where q is 0, 1, 2, or 3; and, where n is 0, 1, 2, 3, 4 or 5; or, a pharmaceutically acceptable salt thereof, to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly, those affected or mediated by the androgen receptor.

  本发明涉及一种具有化学式1、2或3的化合物：其中A为N或—CR0—，其中R0为氢、C1-C6直链或支链烷基等，Z为—CRe—或—N—，其中Re为氢、C1-C6直链或支链烷基等；R1为氢、C1-C6直链或支链烷基等；R2独立地为氢或C1-C6直链或支链烷基；R3和R4独立地为氢、C1-C6直链或支链烷基等；R5和R6独立地为氢或C1-C6直链或支链烷基等；R8为氢、C1-C6直链或支链烷基等；R9和R10独立地为氢或C1-C6直链或支链烷基等；Q为—CO—、—(CH2)q—、—(CHRs)q—或(CRsRt)q—，其中Rs和Rt独立地为C1-C6直链或支链烷基、芳基、烷基芳基、杂芳基或烷基杂芳基；其中q为0、1、2或3；n为0、1、2、3、4或5；或其药学上可接受的盐，以及含有这种化合物的组合物；以及这种化合物在治疗各种疾病中的用途，特别是那些受雄激素受体影响或介导的疾病。
• MIDLAND, M. M.;KWON, YOUNG, C., TETRAHEDRON LETT., 1985, 26, N 41, 5013-5016
  作者：MIDLAND, M. M.、KWON, YOUNG, C.

  DOI：——

  日期：——
• METHODS OF USE AND COMBINATIONS
  申请人：Pfizer Inc.

  公开号：US20170252352A1

  公开（公告）日：2017-09-07

  The present invention relates to a compound of Formula 1, 2 or 3: I II III wherein A is N or —CR 0 —, where R 0 is hydrogen, C 1 -C 6 linear or branched chain alkyl, etc., Z is —CR e —, or, —N—, where R e is hydrogen, C 1 -C 6 linear or branched chain alkyl, etc.; R 1 is hydrogen, C 1 -C 6 linear or branched chain alkyl, etc.; R 2 are independently hydrogen or C 1 -C 6 linear or branched chain alkyl; R 3 and R 4 are independently hydrogen, C 1 C 6 linear or branched chain alkyl, etc.; R 5 and R 6 are independently hydrogen or C 1 -C 6 linear or branched chain alkyl, etc.; R 8 is hydrogen, C 1 -C 6 linear or branched chain alkyl, etc.; R 9 and R 10 are independently hydrogen or C 1 -C 6 linear or branched chain alkyl, etc.; Q is —CO—, —(CH 2 ) q —, —(CHR s ) q —, or —(CR s R t ) q —, where R s and R t are independently C 1 -C 6 linear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl; where q is 0, 1, 2, or 3; and, where n is 0, 1, 2, 3, 4 or 5; or, a pharmaceutically acceptable salt thereof, for the treatment of certain diseases, particularly those affected or mediated by the androgen receptor; to combinations comprising such compounds with a second pharmaceutically active ingredient; to compositions containing such combinations; and to such combinations for the treatment of various diseases, particularly, those affected or mediated by the androgen receptor.
• US9328104B2
  申请人：——

  公开号：US9328104B2

  公开（公告）日：2016-05-03
• Studies on Chirality Transfer in the [2,3] Sigmatropic Rearrangement of Anions Derived from Trialkylstannylmethyl Allylic Ethers. Stereospecific Synthesis of (2R)-3-Benzyloxy-2-methylpropanol.
  作者：M.Mark Midland、Young C. Kwon

  DOI：10.1016/s0040-4039(01)80840-6

  日期：1985.1

  Virtually complete chirality transfer is observed in the [2,3] sigmatropic rearrangement of the anion derived from trialkylstanylmethyl ()- or ()-allylic ethers.

  在衍生自三烷基锡烷基甲基（）-或（）-烯丙基醚的阴离子的[2,3]σ重排中观察到几乎完全的手性转移。